rosiglitazone has been researched along with glipizide in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (60.87) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gomis, R; Jones, NP; Patwardhan, RN; Squatrito, S; Wolffenbuttel, BH | 1 |
| Rochester, CD; Samuel, J | 1 |
| Bell, CF; Botteman, MF; Braunstein, SN; Devine, ST; Ramsdell, JW; Stephens, JM | 1 |
| Desai-Krieger, D; Lin, ZJ; Shum, L | 1 |
| Digman, C; Klein, AK; Pittas, AG | 1 |
| Dirani, RG; Freed, MI; Goldstein, BJ; Heise, MA; Kravitz, B; O'neill, MC; Porter, LE; Rosenstock, J; Vinik, AI | 1 |
| Choudhury, H; Harisudhan, T; Mullangi, R; Srinivas, NR; Venkatesh, P | 1 |
| Bradley, JD; Geary, RS; Kwon, Y; van Lier, JJ; VanVliet, AA; Watanabe, T; Wedel, M | 1 |
| Elo, B; Govorko, D; Villano, CM; White, LA | 1 |
| Bussel, II; Felgner, J; Jafari, M; Khodayari, B; Mueller, LD; Rose, MR | 1 |
| Cannon, CP; Fitzgerald, PJ; Gerstein, HC; Kolatkar, NS; Kravitz, BG; Nesto, RW; Ratner, RE; Serruys, PW; Van Es, GA; Zalewski, A | 1 |
| Agrawal, A | 1 |
| Brugaletta, S; García-García, HM; Garg, S; Huang, C; Kolatkar, NS; Kravitz, BG; Miller, DM; Morocutti, G; Nesto, RW; Ratner, RE; Serruys, PW | 1 |
| Boyko, EJ; Floyd, JS; Forsberg, CW; Moore, K; Riley, K; Smith, NL; Wheeler, S | 1 |
| Adanichkin, N; Campbell, JM; Kurmis, R; Munn, Z | 1 |
| Jannetto, PJ; Langman, LJ | 1 |
3 review(s) available for rosiglitazone and glipizide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Combination agents for diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.
Topics: Burns; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Exenatide; Glipizide; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Metformin; Pioglitazone; Rosiglitazone; Secretagogues; Sulfonylurea Compounds | 2018 |
5 trial(s) available for rosiglitazone and glipizide
| Article | Year |
|---|---|
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Fructosamine; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Triglycerides | 2000 |
Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.
Topics: Age Factors; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Titrimetry; Treatment Outcome; Triglycerides | 2006 |
Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone.
Topics: Administration, Oral; Adult; Blood Proteins; Drug Interactions; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Oligoribonucleotides; Protein Binding; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2006 |
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.
Topics: Adult; Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones; Ultrasonography, Interventional | 2008 |
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug-Eluting Stents; Female; Glipizide; Humans; Hyperplasia; Hypoglycemic Agents; Male; Metals; Middle Aged; Neointima; Predictive Value of Tests; Prospective Studies; Prosthesis Design; Rosiglitazone; Stents; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
15 other study(ies) available for rosiglitazone and glipizide
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
Topics: Carbamates; Cohort Studies; Decision Trees; Diabetes Mellitus, Type 2; Direct Service Costs; Drug Costs; Drug Therapy, Combination; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Managed Care Programs; Markov Chains; Metformin; Models, Economic; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2003 |
Simultaneous determination of glipizide and rosiglitazone unbound drug concentrations in plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Dialysis; Drug Stability; Glipizide; Humans; Hypoglycemic Agents; Quality Control; Reproducibility of Results; Rosiglitazone; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Thiazolidinediones | 2004 |
Leukopenia and thrombocytopenia caused by thiazolidinediones.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glipizide; Humans; Hypoglycemic Agents; Leukopenia; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Thrombocytopenia | 2005 |
Simultaneous estimation of six anti-diabetic drugs--glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human p
Topics: Carbamates; Chromatography, High Pressure Liquid; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Molecular Structure; Pioglitazone; Piperidines; Reproducibility of Results; Rosiglitazone; Thiazolidinediones | 2006 |
Larval zebrafish as a model for glucose metabolism: expression of phosphoenolpyruvate carboxykinase as a marker for exposure to anti-diabetic compounds.
Topics: Animals; Blood Glucose; Cyclic AMP; Dexamethasone; Glipizide; Hypoglycemic Agents; Larva; Metformin; Models, Animal; Phosphoenolpyruvate Carboxykinase (GTP); Rosiglitazone; Thiazolidinediones; Tretinoin; Zebrafish | 2007 |
Pioglitazone: an anti-diabetic compound with anti-aging properties.
Topics: Animals; Basal Metabolism; Dose-Response Relationship, Drug; Drosophila melanogaster; Fertility; Glipizide; Hypoglycemic Agents; Insulin; Longevity; Metformin; Models, Biological; Pioglitazone; Population Density; Research Design; Rosiglitazone; Sexual Behavior, Animal; Signal Transduction; Thiazolidinediones; Time Factors | 2007 |
Effectiveness of the early addition of rosiglitazone to control hyperglycemia after unsuccessful submaximal sulphonylurea monotherapy: the Rosiglitazone Early Versus SULphonylurea Titration (RESULT) Study.
Topics: Age Factors; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Titrimetry; Treatment Outcome; Triglycerides | 2009 |
Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.
Topics: Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; United States; Veterans | 2013 |
Analysis of Hypoglycemic Drugs by Liquid Chromatography-Tandem Mass Spectrometry.
Topics: Chlorpropamide; Chromatography, High Pressure Liquid; Chromatography, Liquid; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Nateglinide; Pioglitazone; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tolazamide; Tolbutamide | 2024 |